Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $246 from $242 and keeps a Buy rating on the shares. The company reported a Q1 beat on commercial momentum, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
- Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
- Neurocrine Remains Top Pick on Durable Multi‑Year Growth Outlook; Buy Rating Reiterated with Unchanged $200 Price Target
- Neurocrine Biosciences Delivers Record Quarter, Eyes 2027
- Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand